safinamide has been researched along with levodopa in 53 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | safinamide (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.66) | 29.6817 |
| 2010's | 19 (35.85) | 24.3611 |
| 2020's | 31 (58.49) | 2.80 |
| Authors | Studies |
|---|---|
| Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P | 1 |
| Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L | 1 |
| Chen, JJ; Fernandez, HH | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M | 1 |
| Bonizzoni, E; Cattaneo, C; Sardina, M | 1 |
| Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH | 1 |
| Blair, HA; Dhillon, S | 1 |
| deSouza, RM; Schapira, A | 1 |
| Müller, T | 2 |
| Gago, MF; Magalhães, R; Marques, P; Moreira, PS; Salgado, AJ; Sousa, N; Teixeira, FG | 1 |
| Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V | 1 |
| Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Parambi, DGT | 1 |
| Abdelalem Aziz Ahmed, M | 1 |
| Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A | 2 |
| Ishida, T; Koebisu, M | 1 |
| El-Kosasy, AM; Hussein, LA; Mohamed, NM; Salama, NN | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G | 1 |
| Carrara, F; Corrù, F; Elia, AE; Fittipaldo, VA; Giossi, R; Lo Re, F; Mazzari, M; Pani, A; Scaglione, F; Schicchi, A; Senatore, M; Tramacere, I | 1 |
| De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A | 1 |
| Abbruzzese, G; Barone, P; Lopiano, L; Stocchi, F | 1 |
| Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y | 1 |
| Larson, D; Simuni, T | 1 |
| Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY | 1 |
| Alonso-Cánovas, A; Baena-Álvarez, B; Beltrán-Corbellini, Á; Chico-García, JL; López-Sendón, JL; Martínez-Castrillo, JC; Pagonabarraga, J; Pareés, I; Parra-Díaz, P; Pérez-Torre, P; Rodríguez-Jorge, F | 1 |
| Huot, P; Lachance, L | 1 |
| Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Hirano, M; Isono, C; Nagai, Y; Samukawa, M | 1 |
| Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
| Andreozzi, V; Cattaneo, C; Oliveros, C; Pellecchia, MT; Picillo, M; Russillo, MC | 1 |
21 review(s) available for safinamide and levodopa
| Article | Year |
|---|---|
Safinamide: from molecular targets to a new anti-Parkinson drug.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Brain Ischemia; Disease Models, Animal; Gerbillinae; Humans; Kainic Acid; Levodopa; Mice; MPTP Poisoning; Neurons; Rats; Veratridine | 2006 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2014 |
Management of Parkinson׳s disease: Current and future pharmacotherapy.
Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; Parkinson Disease | 2015 |
Safinamide: A Review in Parkinson's Disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2017 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Safinamide: a new hope for Parkinson's disease?
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2019 |
Safinamide in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult | 2020 |
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2021 |
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Treatment Outcome | 2021 |
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide | 2023 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
13 trial(s) available for safinamide and levodopa
| Article | Year |
|---|---|
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pilot Projects; Treatment Outcome | 2006 |
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Topics: Antiparkinson Agents; China; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
The effects of safinamide according to gender in Chinese parkinsonian patients.
Topics: Antiparkinson Agents; Double-Blind Method; East Asian People; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life | 2023 |
19 other study(ies) available for safinamide and levodopa
| Article | Year |
|---|---|
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome | 2013 |
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2018 |
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
[Safinamide Mesilate (Equfina
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Mesylates; Rats; Tablets | 2020 |
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2020 |
New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma.
Topics: Alanine; Benzylamines; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Levodopa; Limit of Detection; Linear Models; Ondansetron; Reproducibility of Results; Tablets | 2020 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2022 |
Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease | 2022 |
Pemphigoid-like Skin Lesions Following Introduction of Safinamide.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Pemphigoid, Bullous | 2023 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
The effects of safinamide on dysphagia in Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies | 2023 |
SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Topics: Benzylamines; Humans; Levodopa; Parkinson Disease; Synapses | 2023 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |